Sage's oral innovative antidepressant SAGE-2173 trial ROBIN reached the main and secondary ends of the trial

today, Sage Therapeutics(http://announced that it had reached the primary and secondary point of the trial in theof the 3-stagetrial (http://ROBIN, aof(http:// for the treatment of women with postpartum depression (PPD), in the(http://) of the innovative anti-depressivedrug in the studyGABA system is the main inhibitory signaling pathway in the brain and CNS, which is important for the regulation of CNS functionSAGE-217 is a next-generation forward other regulator selectively targeted at synaptic and synaptic gabA receptors, and has pharmacokinetic characteristics suitable for oral administrationSAGE-217 is expected to be a boon for patients with severe depression (MDD) and PDD by regulating the GABA systemstudyphase 3 trial called ROBIN to assess the effectiveness, safety and pharmacokinetic properties of SAGE-217 (30 mg) treatment of adult women with severe PPD (HAMD-17) of depressionat the main endpoint of the trial, from day 3, the decrease in HAMD-17 scores in the SAGE-217 group compared to the placebo group showed a statistically significant difference (-12.5 vs 9.8; p.0255) and remained different at every point during the two-week treatment period (-17.8 to 13.6; p.0029) This difference was also maintained during the follow-up period during the fourth week (-19.2 vs 15.1; p-0.0027; two weeks after treatment with SAGE-217, 45% of patients reached remission (HAMD-17 s7), compared with 23% in the placebo group (p-0.0122); at the end of the follow-up period of the fourth week, 53% of patients treated with SAGE-217 reached remission, compared with 30% in the placebo group (p-0.0102
); After two weeks of treatment, 72% of patients received a response (50% improved baseline HAMD-17 score), compared with 48% in the placebo group (p-0.0050), 75% of patients treated with SAGE-217 at the end of the fourth week, compared with 57% in the placebo group (p-0.0220); with a Montgomery-Sberg depression score (MADRS) after two weeks of treatment, after two weeks of treatment, A decrease in MADRS scores in the SAGE-217 group compared to a placebo group showed a statistically significant difference (-22 ratio-18; p-0.0182) other secondary endpoints, including tests on the Hamilton Anxiety Assessment Scale (HAM-A) and clinical general impression-improvement (CGI-I) scales (http:// and showed that SAGE-217 improved depressive symptoms more effectively than placebos 　　SAGE-217 is generally well tolerated and its safety is consistent with what was seen in earlier SAGE-217 trials